The efficacy and safety of CAR-T cell therapy in patients with refractory ALL and concomitant HBV infection


Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: CAR-T cells from HBV patients displayed potent antileukemic activity.


  1. 1.

    Rossig C, Pule M, Altvater B, Saiagh S, Wright G, Ghorashian S, et al. Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia. Leukemia. 2017;31:1087–95.

    CAS  Article  Google Scholar 

  2. 2.

    Park JH, Riviere I, Gonen M, Wang X, Senechal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378:449–59.

    CAS  Article  Google Scholar 

  3. 3.

    Cao W, Wei J, Wang N, Xu H, Xiao M, Huang L, et al. Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy. Blood. 2020; blood.2020004907.

  4. 4.

    Strati P, Nastoupil LJ, Fayad LE, Samaniego F, Adkins S, Neelapu SS. Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection. Blood. 2019;133:2800–2.

    CAS  Article  Google Scholar 

  5. 5.

    Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546–55.

    Article  Google Scholar 

  6. 6.

    Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy—assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15:47–62.

    CAS  Article  Google Scholar 

  7. 7.

    Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560–99.

    Article  Google Scholar 

  8. 8.

    Weng J, Lai P, Qin L, Lai Y, Jiang Z, Luo C, et al. A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia. J Hematol Oncol. 2018;11:25.

    Article  Google Scholar 

  9. 9.

    Lai Y, Weng J, Wei X, Qin L, Lai P, Zhao R, et al. Toll-like receptor 2 costimulation potentiates the antitumor efficacy of CAR T Cells. Leukemia. 2018;32:801–8.

    CAS  Article  Google Scholar 

Download references


This work was supported by the National Natural Science Foundation of China (No. 81870121); Guangdong Basic and Applied Basic Research Foundation (No. 2019A1515010094); and the Project of Administration of Traditional Chinese Medicine of Guangdong Province (20191008).

Author information




J Weng, X Du, P Li, and P Lai conceived and designed the study. P Lai, X Chen, L Qin, Z Jiang, C Luo, X Huang, S Wu, W Ling, Y Wang, J Wang, C Deng, and L Huang performed the main experiments and analyses. L Zeng, Z Lu, L Zhong, P Liao, M Li, D Chen, P Wu, and S Geng assisted in diagnostic interpretation of patient samples, and clinical monitor of patients’ condition. P Lai, J Weng, X Du, and P Li wrote the paper. Z Tang, and D Pei provide conceptual advice and revised the paper. All authors read and approved the final paper.

Corresponding authors

Correspondence to Xin Du or Peng Li or Jianyu Weng.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Lai, P., Chen, X., Qin, L. et al. The efficacy and safety of CAR-T cell therapy in patients with refractory ALL and concomitant HBV infection. Leukemia (2020).

Download citation